AQR Capital Management
BTAI icon

AQR Capital Management’s BioXcel Therapeutics BTAI Stock Holding History

AQR Capital Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-898
Closed -$18.4K – 2773
2024
Q2 		$18.4K Buy
+898
New +$30.1K ﹤0.01% 2573
2021
Q2 		– Sell
-544
Closed -$376K – 2230
2021
Q1 		$376K Hold
544
– – ﹤0.01% 1936
2020
Q4 		$402K Hold
544
– – ﹤0.01% 1862
2020
Q3 		$377K Sell
544
-50
-8% -$37.5K ﹤0.01% 1844
2020
Q2 		$504K Sell
594
-358
-38% -$233K ﹤0.01% 1743
2020
Q1 		$340K Buy
+952
New +$342K ﹤0.01% 1725

Other funds holding BTAI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

AQR Capital Management's BTAI Position: Q3 2024 in Review

AQR Capital Management sold out of BioXcel Therapeutics (BTAI) in Q3 2024, closing a stake of 898 shares — an estimated $18.4K sold.

AQR Capital Management first reported a position in BTAI in Q1 2020 and held it in 6 quarters. The position peaked at $504K in Q2 2020. 49 funds tracked by Wall St. Rank hold BTAI as of Q3 2024.

  • AQR Capital Management reported no remaining BioXcel Therapeutics position as of Q3 2024 after selling out during the quarter.
  • AQR Capital Management sold 898 BioXcel Therapeutics shares in Q3 2024, an estimated $18.4K.
  • AQR Capital Management first reported a position in BioXcel Therapeutics in Q1 2020 and held it in 6 quarters.
  • AQR Capital Management's BioXcel Therapeutics position peaked at $504K in Q2 2020.
  • 49 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2024.

Based on AQR Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.